[{"id":"a9f39237-1737-4421-910a-0e37d38262b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05083754","created_at":"2023-11-27T22:14:37.322Z","updated_at":"2025-02-25T12:28:25.580Z","phase":"Phase 1","brief_title":"Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma","source_id_and_acronym":"NCT05083754","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" PD-L1 • MSI • CD8 • PD-1 • CD4 • ICOS","pipe":"","alterations":" ","tags":["PD-L1 • MSI • CD8 • PD-1 • CD4 • ICOS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • carmustine • Zynyz (retifanlimab-dlwr)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/31/2022","start_date":" 08/31/2022","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-24"},{"id":"f5056d6b-3ffd-4e44-961f-b461e0552213","acronym":"A051902","url":"https://clinicaltrials.gov/study/NCT04803201","created_at":"2021-03-17T15:57:46.362Z","updated_at":"2025-02-25T14:15:53.168Z","phase":"Phase 2","brief_title":"Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma","source_id_and_acronym":"NCT04803201 - A051902","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" PD-1 • TNFRSF8 • BCL6 • CXCL13 • ICOS • MME","pipe":" | ","alterations":" TNFRSF8 expression","tags":["PD-1 • TNFRSF8 • BCL6 • CXCL13 • ICOS • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • azacitidine • cyclophosphamide • etoposide IV • Copiktra (duvelisib) • vincristine • prednisone • Onureg (azacitidine oral) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 10/08/2021","start_date":" 10/08/2021","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-18"},{"id":"6fa362b2-89c2-4884-87bd-ac57c53e5ca0","acronym":"E4412","url":"https://clinicaltrials.gov/study/NCT01896999","created_at":"2021-01-29T07:05:03.634Z","updated_at":"2025-02-25T16:36:17.132Z","phase":"Phase 1/2","brief_title":"Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma","source_id_and_acronym":"NCT01896999 - E4412","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-1 • CD4 • LGALS1 • ICOS","pipe":" | ","alterations":" TNFRSF8 expression","tags":["PD-1 • CD4 • LGALS1 • ICOS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Adcetris (brentuximab vedotin) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 03/07/2014","start_date":" 03/07/2014","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-06"},{"id":"44b80189-528f-4f15-a751-b2fa0ad145eb","acronym":"PCR-MIB","url":"https://clinicaltrials.gov/study/NCT02662062","created_at":"2025-02-25T18:11:21.641Z","updated_at":"2025-02-25T18:11:21.641Z","phase":"Phase 2","brief_title":"Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer","source_id_and_acronym":"NCT02662062 - PCR-MIB","lead_sponsor":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","biomarkers":" CD20 • CD8 • PD-1 • LAG3 • CD4 • ICOS • FOXP3","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD8 • PD-1 • LAG3 • CD4 • ICOS • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 07/11/2017","start_date":" 07/11/2017","primary_txt":" Primary completion: 05/12/2022","primary_completion_date":" 05/12/2022","study_txt":" Completion: 08/26/2024","study_completion_date":" 08/26/2024","last_update_posted":"2025-01-27"},{"id":"2c6b4f69-4124-49bc-8cc4-6915ea81dc11","acronym":"INDUCE-1","url":"https://clinicaltrials.gov/study/NCT02723955","created_at":"2021-01-17T17:58:41.023Z","updated_at":"2025-02-25T16:04:31.793Z","phase":"Phase 1","brief_title":"Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)","source_id_and_acronym":"NCT02723955 - INDUCE-1","lead_sponsor":"GlaxoSmithKline","biomarkers":" MSI • ICOS","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • ICOS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • docetaxel • 5-fluorouracil • pemetrexed • Jemperli (dostarlimab-gxly) • bintrafusp alfa (M7824) • cobolimab (TSR-022) • feladilimab (GSK3359609) • GSK3174998"],"overall_status":"Completed","enrollment":" Enrollment 829","initiation":"Initiation: 06/23/2016","start_date":" 06/23/2016","primary_txt":" Primary completion: 07/05/2023","primary_completion_date":" 07/05/2023","study_txt":" Completion: 07/05/2023","study_completion_date":" 07/05/2023","last_update_posted":"2024-12-27"},{"id":"9b80d640-ac33-4411-ad4d-9614359a1e32","acronym":"","url":"https://clinicaltrials.gov/study/NCT02265536","created_at":"2025-07-19T14:00:09.317Z","updated_at":"2025-07-19T14:00:09.317Z","phase":"Phase 1","brief_title":"A Study of LY3022855 In Participants With Breast or Prostate Cancer","source_id_and_acronym":"NCT02265536","lead_sponsor":"Eli Lilly and Company","biomarkers":" CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • IL2 • ICOS • IL10 • CD14 • FOXP3 • IL1B","pipe":"","alterations":" ","tags":["CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • IL2 • ICOS • IL10 • CD14 • FOXP3 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LY3022855"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 11/03/2017","primary_completion_date":" 11/03/2017","study_txt":" Completion: 11/03/2017","study_completion_date":" 11/03/2017","last_update_posted":"2024-10-28"},{"id":"879fd467-51b3-46e4-9863-a9475f8f4f72","acronym":"Oracle","url":"https://clinicaltrials.gov/study/NCT03593018","created_at":"2021-01-18T17:39:39.095Z","updated_at":"2025-02-25T14:27:18.930Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL","source_id_and_acronym":"NCT03593018 - Oracle","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" PD-1 • BCL6 • CXCL13 • ICOS • MME","pipe":" | ","alterations":" PD-1 expression","tags":["PD-1 • BCL6 • CXCL13 • ICOS • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • azacitidine • bendamustine • Istodax (romidepsin) • Onureg (azacitidine oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 11/09/2018","start_date":" 11/09/2018","primary_txt":" Primary completion: 02/10/2021","primary_completion_date":" 02/10/2021","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-10-09"},{"id":"4f28ce0c-9a5a-4a61-b5dd-312c3d0839fe","acronym":"KEYNOTE-A10","url":"https://clinicaltrials.gov/study/NCT03058289","created_at":"2021-01-18T15:03:51.688Z","updated_at":"2025-02-25T14:37:17.876Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6","source_id_and_acronym":"NCT03058289 - KEYNOTE-A10","lead_sponsor":"Intensity Therapeutics, Inc.","biomarkers":" MSI • CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • CD4 • IL2 • ICOS • IL10 • FOXP3 • IL1B","pipe":"","alterations":" ","tags":["MSI • CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • CD4 • IL2 • ICOS • IL10 • FOXP3 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Yervoy (ipilimumab) • cisplatin/vinblastine/SHAO-FA (INT230-6)"],"overall_status":"Completed","enrollment":" Enrollment 111","initiation":"Initiation: 02/09/2017","start_date":" 02/09/2017","primary_txt":" Primary completion: 02/22/2023","primary_completion_date":" 02/22/2023","study_txt":" Completion: 02/22/2023","study_completion_date":" 02/22/2023","last_update_posted":"2024-08-13"},{"id":"114d9c89-e0e5-473e-a324-f2022f9b4244","acronym":"","url":"https://clinicaltrials.gov/study/NCT04465643","created_at":"2021-01-18T21:27:49.677Z","updated_at":"2025-02-25T14:29:26.270Z","phase":"Phase 1","brief_title":"Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor","source_id_and_acronym":"NCT04465643","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" PD-L1 • CD20 • CD8 • PD-1 • LAG3 • CD276 • CTLA4 • PD-L2 • VTCN1 • HAVCR2 • IL2RA • CD163 • TIGIT • PTPRC • NCAM1 • ICOS • CD14 • CD68 • GZMB • ITGAM • BTLA • FOXP3 • MRC1 • ISG20","pipe":"","alterations":" ","tags":["PD-L1 • CD20 • CD8 • PD-1 • LAG3 • CD276 • CTLA4 • PD-L2 • VTCN1 • HAVCR2 • IL2RA • CD163 • TIGIT • PTPRC • NCAM1 • ICOS • CD14 • CD68 • GZMB • ITGAM • BTLA • FOXP3 • MRC1 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/08/2021","start_date":" 06/08/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-06-21"},{"id":"dae7e1e4-54ce-455f-95d9-b6fe1e15a02c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01194271","created_at":"2021-01-18T04:46:46.549Z","updated_at":"2025-02-25T14:32:19.111Z","phase":"Phase 2","brief_title":"Neoadjuvant Ipilimumab in Prostate Cancer","source_id_and_acronym":"NCT01194271","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD8 • CD4 • ICOS","pipe":"","alterations":" ","tags":["CD8 • CD4 • ICOS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • leuprolide acetate for depot suspension"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 09/01/2010","start_date":" 09/01/2010","primary_txt":" Primary completion: 10/01/2015","primary_completion_date":" 10/01/2015","study_txt":" Completion: 10/01/2015","study_completion_date":" 10/01/2015","last_update_posted":"2024-06-06"},{"id":"957dbc1c-015e-40ca-955c-7ba6d6d32576","acronym":"","url":"https://clinicaltrials.gov/study/NCT06086132","created_at":"2023-10-17T15:12:38.701Z","updated_at":"2024-07-02T16:35:05.109Z","phase":"","brief_title":"Detection and Prevention of Cancer-Related Cardiovascular Toxicity Registry","source_id_and_acronym":"NCT06086132","lead_sponsor":"University of Bologna","biomarkers":" ICOS","pipe":"","alterations":" ","tags":["ICOS"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 10000","initiation":"Initiation: 07/01/2024","start_date":" 07/01/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-08"},{"id":"f003bb6c-5459-49c1-947d-35ec28b1d2c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04135079","created_at":"2024-02-23T15:25:03.657Z","updated_at":"2024-07-02T16:35:04.833Z","phase":"","brief_title":"Immune Profiling in Multiple Myeloma","source_id_and_acronym":"NCT04135079","lead_sponsor":"Mario Boccadoro","biomarkers":" PD-1 • IFNG • IL6 • TNFA • IL2RA • ICOS • IL10 • CD27 • ICOSLG • TGFB1 • CD31 • IL17A • IL1B • PECAM1 • CD86","pipe":"","alterations":" ","tags":["PD-1 • IFNG • IL6 • TNFA • IL2RA • ICOS • IL10 • CD27 • ICOSLG • TGFB1 • CD31 • IL17A • IL1B • PECAM1 • CD86"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 04/15/2019","start_date":" 04/15/2019","primary_txt":" Primary completion: 04/28/2021","primary_completion_date":" 04/28/2021","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-05-08"},{"id":"b75c8e0c-7a34-42e8-acb6-f56117fba765","acronym":"","url":"https://clinicaltrials.gov/study/NCT03542266","created_at":"2022-11-13T19:37:00.102Z","updated_at":"2025-02-25T14:27:01.502Z","phase":"Phase 2","brief_title":"CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma","source_id_and_acronym":"NCT03542266","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" ALK • PD-1 • BCL6 • CXCL13 • ICOS • MME","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK • PD-1 • BCL6 • CXCL13 • ICOS • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • Onureg (azacitidine oral)"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 06/01/2018","start_date":" 06/01/2018","primary_txt":" Primary completion: 03/25/2020","primary_completion_date":" 03/25/2020","study_txt":" Completion: 07/25/2022","study_completion_date":" 07/25/2022","last_update_posted":"2023-08-22"},{"id":"d8ecd871-ab7d-41e3-9288-1a7df97b0501","acronym":"UCARE","url":"https://clinicaltrials.gov/study/NCT05921279","created_at":"2023-07-06T17:11:05.365Z","updated_at":"2024-07-02T16:35:42.038Z","phase":"","brief_title":"Understanding CARdiac Events in Breast Cancer","source_id_and_acronym":"NCT05921279 - UCARE","lead_sponsor":"National University of Ireland, Galway, Ireland","biomarkers":" ICOS","pipe":"","alterations":" ","tags":["ICOS"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 01/14/2023","start_date":" 01/14/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2023-07-25"},{"id":"16ef9d21-8207-47e4-a9b8-6b7317828b9e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04703426","created_at":"2021-01-19T20:51:03.494Z","updated_at":"2024-07-02T16:35:47.533Z","phase":"Phase 2","brief_title":"Sargramostim (GM-CSF) + PD-1","source_id_and_acronym":"NCT04703426","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CD4 • ICOS","pipe":"","alterations":" ","tags":["CD4 • ICOS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Leukine (sargramostim)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/16/2021","start_date":" 04/16/2021","primary_txt":" Primary completion: 06/10/2024","primary_completion_date":" 06/10/2024","study_txt":" Completion: 06/09/2025","study_completion_date":" 06/09/2025","last_update_posted":"2023-05-22"},{"id":"23758911-8745-4e04-b970-f675198d8588","acronym":"PRINCESS","url":"https://clinicaltrials.gov/study/NCT05821751","created_at":"2023-04-20T14:03:53.992Z","updated_at":"2024-07-02T16:35:50.012Z","phase":"","brief_title":"The Effect of Prebiotic Inulin on Patients Affected by R/M HNSCC Treated With Immune Checkpoint Inhibitors","source_id_and_acronym":"NCT05821751 - PRINCESS","lead_sponsor":"Fondazione del Piemonte per l'Oncologia","biomarkers":" PD-L1 • PD-1 • IL6 • LAG3 • CXCL8 • CXCL10 • HAVCR2 • IL2 • ICOS • IL10 • CCL2 • IL13 • IL15 • IL21 • IL4 • IL5","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • IL6 • LAG3 • CXCL8 • CXCL10 • HAVCR2 • IL2 • ICOS • IL10 • CCL2 • IL13 • IL15 • IL21 • IL4 • IL5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/02/2021","start_date":" 12/02/2021","primary_txt":" Primary completion: 12/02/2024","primary_completion_date":" 12/02/2024","study_txt":" Completion: 12/02/2025","study_completion_date":" 12/02/2025","last_update_posted":"2023-04-20"},{"id":"aa427175-54cc-421c-9eb3-20e2eec8ad01","acronym":"","url":"https://clinicaltrials.gov/study/NCT03703375","created_at":"2021-01-18T18:08:54.175Z","updated_at":"2024-07-02T16:36:00.520Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma","source_id_and_acronym":"NCT03703375","lead_sponsor":"Celgene","biomarkers":" PD-1 • BCL6 • CXCL13 • ICOS • MME","pipe":"","alterations":" ","tags":["PD-1 • BCL6 • CXCL13 • ICOS • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Istodax (romidepsin) • Onureg (azacitidine oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 11/06/2018","start_date":" 11/06/2018","primary_txt":" Primary completion: 02/10/2021","primary_completion_date":" 02/10/2021","study_txt":" Completion: 02/29/2024","study_completion_date":" 02/29/2024","last_update_posted":"2022-11-14"},{"id":"4d8688dd-9d27-4d21-bc86-16de9a5f1ff7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04118868","created_at":"2021-01-18T20:07:51.357Z","updated_at":"2024-07-02T16:36:02.674Z","phase":"Phase 1b","brief_title":"Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.","source_id_and_acronym":"NCT04118868","lead_sponsor":"Sorrento Therapeutics, Inc.","biomarkers":" CD8 • PD-1 • LAG3 • HAVCR2 • CD4 • ICOS • GZMB","pipe":"","alterations":" ","tags":["CD8 • PD-1 • LAG3 • HAVCR2 • CD4 • ICOS • GZMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 08/31/2022","start_date":" 08/31/2022","primary_txt":" Primary completion: 01/29/2024","primary_completion_date":" 01/29/2024","study_txt":" Completion: 03/27/2024","study_completion_date":" 03/27/2024","last_update_posted":"2022-10-11"},{"id":"d3399d53-3142-4fb8-8731-3da5f0cf0026","acronym":"TITAN-RCC","url":"https://clinicaltrials.gov/study/NCT02917772","created_at":"2021-08-04T19:53:08.805Z","updated_at":"2025-02-25T14:36:42.250Z","phase":"Phase 2","brief_title":"Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma","source_id_and_acronym":"NCT02917772 - TITAN-RCC","lead_sponsor":"AIO-Studien-gGmbH","biomarkers":" CD8 • PD-1 • PD-L2 • IL2RA • CD69 • ICOS • IL10 • CD14 • CD27 • LAMP1 • ITGAM • FAS • FOXP3 • IL17A • IL3RA • ITGAX • B3GAT1 • CD1C • CLEC4C","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • PD-L2 • IL2RA • CD69 • ICOS • IL10 • CD14 • CD27 • LAMP1 • ITGAM • FAS • FOXP3 • IL17A • IL3RA • ITGAX • B3GAT1 • CD1C • CLEC4C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Completed","enrollment":" Enrollment 200","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 10/01/2022","study_completion_date":" 10/01/2022","last_update_posted":"2022-10-06"},{"id":"e576c294-0554-44f5-8458-3b487ddaffca","acronym":"","url":"https://clinicaltrials.gov/study/NCT02592551","created_at":"2021-01-18T12:34:52.727Z","updated_at":"2024-07-02T16:36:03.210Z","phase":"Phase 2","brief_title":"MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma","source_id_and_acronym":"NCT02592551","lead_sponsor":"Baylor College of Medicine","biomarkers":" PD-L1 • CD8 • CD4 • ICOS","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • CD8 • CD4 • ICOS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 05/11/2016","start_date":" 05/11/2016","primary_txt":" Primary completion: 08/06/2019","primary_completion_date":" 08/06/2019","study_txt":" Completion: 09/01/2022","study_completion_date":" 09/01/2022","last_update_posted":"2022-09-29"},{"id":"b5ce9f6f-90bd-4e6c-8af0-4771e28aea48","acronym":"","url":"https://clinicaltrials.gov/study/NCT03021993","created_at":"2021-01-18T14:52:12.866Z","updated_at":"2025-02-25T14:37:08.309Z","phase":"Phase 2","brief_title":"Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer","source_id_and_acronym":"NCT03021993","lead_sponsor":"Medical University of South Carolina","biomarkers":" CD8 • IFNG • CD4 • CD69 • ICOS • IL10 • GZMB • TGFB1 • FOXP3","pipe":" | ","alterations":" CD8 expression • IFNG expression • IL2 expression","tags":["CD8 • IFNG • CD4 • CD69 • ICOS • IL10 • GZMB • TGFB1 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression • IFNG expression • IL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 05/30/2017","start_date":" 05/30/2017","primary_txt":" Primary completion: 11/15/2021","primary_completion_date":" 11/15/2021","study_txt":" Completion: 11/15/2021","study_completion_date":" 11/15/2021","last_update_posted":"2021-12-13"},{"id":"da30e10f-e520-4977-a09e-302d2f4b6b4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04001101","created_at":"2021-01-18T19:39:57.498Z","updated_at":"2024-07-02T16:36:20.116Z","phase":"Phase 2","brief_title":"Anti-PD-1 +/- RT for MSI-H Solid Tumors","source_id_and_acronym":"NCT04001101","lead_sponsor":"University of Colorado, Denver","biomarkers":" MSI • CD8 • LAG3 • IL2RA • ICOS • CD1C • CD80","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • CD8 • LAG3 • IL2RA • ICOS • CD1C • CD80"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/10/2019","start_date":" 10/10/2019","primary_txt":" Primary completion: 11/17/2021","primary_completion_date":" 11/17/2021","study_txt":" Completion: 11/17/2021","study_completion_date":" 11/17/2021","last_update_posted":"2021-11-30"},{"id":"c0bf121c-6f22-4255-bac5-d33472b5919a","acronym":"MITO CERV 3","url":"https://clinicaltrials.gov/study/NCT04238988","created_at":"2021-01-18T20:36:32.057Z","updated_at":"2025-02-25T16:09:53.518Z","phase":"Phase 2","brief_title":"Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer","source_id_and_acronym":"NCT04238988 - MITO CERV 3","lead_sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","biomarkers":" PD-L1 • PD-1 • IL6 • CTLA4 • PD-L2 • CD4 • ICOS • IL10 • FAS • FOXP3 • TNFSF4","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • IL6 • CTLA4 • PD-L2 • CD4 • ICOS • IL10 • FAS • FOXP3 • TNFSF4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 02/18/2021","start_date":" 02/18/2021","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2021-08-27"},{"id":"fdcb2f57-9f11-417e-a172-701eb93f7d74","acronym":"","url":"https://clinicaltrials.gov/study/NCT03121417","created_at":"2021-01-18T15:22:44.947Z","updated_at":"2025-02-25T14:37:29.830Z","phase":"Phase 2","brief_title":"Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03121417","lead_sponsor":"Emory University","biomarkers":" EGFR • ALK • CD8 • PD-1 • ICOS","pipe":" | ","alterations":" EGFR mutation • ALK translocation","tags":["EGFR • ALK • CD8 • PD-1 • ICOS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/21/2017","start_date":" 07/21/2017","primary_txt":" Primary completion: 03/09/2019","primary_completion_date":" 03/09/2019","study_txt":" Completion: 03/09/2019","study_completion_date":" 03/09/2019","last_update_posted":"2019-05-21"}]